Clinical trials: Secondary Trauma
Burns
Evaluation of Antimicrobial Soft Silicone, Silver Containing, Foam Dressing, Mepilex Border Ag, in Second Degree Burns
The investigation is designed as an open, non-controlled, post-marketing investigation. Subjects with at least one second degree burn less than 9.5x15 cm in size at 1-3 sites will be included.
- Trial name
- NCT01418482
- Testing
- Mepilex Border Ag
- Where
- 2 sites in Sweden
- Volunteers
- 15 people
- Sponsor
- Molnlycke Health Care AB
Amputation Wound, Peripheral Arterial Disease
Wound Imaging Study to Gather Clinical References for a Device to Assist Selecting Level-of-amputation in PAD Patients
This is a proof-of-concept study to collect images to train a CADe algorithm to predict the correct level of amputation in individuals scheduled for amputation secondary to PAD.
- Trial name
- WISCR (NCT03611361)
- Testing
- SpectralMD DeepView Wound Imaging System 2.0
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- SpectralMD
Acute Deep Partial Thickness Thermal Burns
Applying Platelet Rich Plasma (PRP) Gel to Acute Deep Partial Thickness Thermal Injuries
The study will examine the safety of using a concentration of proteins from a patient's own blood, referred to as platelet rich plasma or (PRP) and applying it to a second degree burn wound.
- Trial name
- NCT02169362
- Testing
- Autologous Platelet Rich Plasma (PRP) Gel (Magellan® Bio-Bandage™)
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- Arteriocyte, Inc.
Dehiscence Wound
Efficacy Evaluation of ActiGraft in Secondary Closure of Abdominal Surgical Wound Dehiscence
This is a prospective, single arm study, consisting of 20 women with abdominal surgical wound dehiscence that requires secondary closure.
- Trial name
- NCT04899466
- Testing
- ActiGraft
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- RedDress Ltd.
Burn
A Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Deep Second-degree Burn Wound
This is a phase I study to evaluate the safety of ALLO-ASC-DFU for the treatment of deep second-degree burn wound patients. ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells.
- Trial name
- NCT02394873
- Testing
- ALLO-ASC-DFU
- Where
- South Korea
- Volunteers
- 5 people
- Sponsor
- Anterogen Co., Ltd.
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral…
- Conditions
- Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin
- Trial name
- ON-5001 (NCT06022029)
- Testing
- ONM-501, Cemiplimab
- Where
- 16 sites in United States, Australia
- Volunteers
- 168 people
- Sponsor
- OncoNano Medicine, Inc.
Pressure Sore, Pressure Ulcer
EmoLED Medical Device Treatment of Second and Third Stage Pressure Ulcers
The present clinical study aims to verify the effectiveness and safety of the blue light photobiomodulation therapy with EmoLED medical device in supporting the reparative process of the area of the second and third stage…
- Conditions
- Pressure Sore, Pressure Ulcer, Pressure Ulcers Stage III, Pressure Ulcers Stage II
- Trial name
- RISE_UP (NCT05130814)
- Testing
- blue light photobiomodulation, cleansing, hyaluronic acid gauze plus polyurethane foam
- Where
- Italy
- Volunteers
- 48 people
- Sponsor
- Emoled
Cutaneous Metastatic Melanoma
Intratumoral Targeted Hyperthermia Therapy (THT) for Stage 3C/3D/4M1 Cutaneous Metastatic Melanoma
This first-in-human device clinical trial investigates the safety and feasibility of GNR-mediated THT in patients with stage 3C/3D/4M1 cutaneous metastatic melanoma unresponsive to systemic to PD-1 immune checkpoint immunotherapy…
- Trial name
- THT-CMM (NCT06894407)
- Testing
- Device: Targeted Hyperthermia Therapy
- Where
- Chile
- Volunteers
- 10 people
- Sponsor
- Sona Nanotech Inc
Bone Metastases, Fractures, Bone
EPIBONE Study: a Prospective Study on Feasibility, Safety and Accuracy
Interventional clinical study to obtain performance and safety data of the EPIONE® device when used for bone percutaneous procedures.
- Conditions
- Bone Metastases, Fractures, Bone, Bone Tumor
- Trial name
- EPIBONE (NCT06376682)
- Testing
- CT-guided bone percutaneous procedure
- Where
- 3 sites in France
- Volunteers
- 34 people
- Sponsor
- Quantum Surgical
Burn Wound, Pressure Ulcers Stage II
Study to Evaluate the Performance and Safety of the Medical Device Argogen
A wound, i.e., a break in the skin, can result from several reasons. Pressure ulcers (also called pressure sores, bed sores and decubitus ulcers) are localized damage to the skin and underlying soft tissue usually over a bony…
- Conditions
- Burn Wound, Pressure Ulcers Stage II, Pressure Ulcers Stage III
- Trial name
- NCT05649332
- Testing
- Argogen (silver zeolite powder)
- Where
- 2 sites in Romania
- Volunteers
- 58 people
- Sponsor
- Signorini Medicale S.r.l.
Head and Neck Cancer, Oral Complications
Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer
RATIONALE: Cevimeline may be effective in treating dry mouth that is caused by radiation therapy for head and neck cancer. It is not yet known if cevimeline is more effective than no therapy in treating dry mouth caused by…
- Conditions
- Head and Neck Cancer, Oral Complications, Radiation Toxicity
- Trial name
- NCT00017511
- Testing
- cevimeline hydrochloride
- Where
- 71 sites in United States
- Sponsor
- Daiichi Sankyo
Burn, Burn Wounds - Partial Thickness (2nd Degree)
Phase II Clinical Trial of KJ101in the Treatment of Deep II Degree Burns
This multicentre, randomised, double-blind, dose-finding, active- and placebo-controlled Phase II clinical trial will evaluate the safety, efficacy, pharmacokinetic profile, and immunogenicity of KJ101 for the debridement of deep…
- Trial name
- NCT07025408
- Testing
- KJ101, Chymotrypsin
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Shanghai Bao Pharmaceuticals Co., Ltd.
Fractures, Bone
A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors
This is a randomized, double-blind, double-dummy study designed to provide bridging data in an Asian population to Amgen's studies of denosumab in subjects with bone metastases from solid tumors.
- Trial name
- NCT01920568
- Testing
- Denosumab 70 mg/mL, Zoledronic acid 4 mg, Calcium supplement
- Where
- 25 sites in China, Singapore and 1 more
- Volunteers
- 487 people
- Sponsor
- GlaxoSmithKline
Burns, Burns Second Degree
CellMist™ Autologous Cells to Treat Deep Second-Degree Burns
The overall purpose of this study is to evaluate the safety of the CellMist™ System in the treatment of deep second degree burns (II°B) in a prospective, multicenter, feasibility pilot study.
- Conditions
- Burns, Burns Second Degree, Burns Deep Second Degree
- Trial name
- CELLMIST1 (NCT04890574)
- Testing
- CellMist™ System
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- RenovaCare, Inc
Primary Osteoarthritis, Secondary Osteoarthritis
Clinical and Radiological Outcomes of Medacta Shoulder System FR
This is a post-marketing surveillance on Medacta Shoulder System
- Conditions
- Primary Osteoarthritis, Secondary Osteoarthritis, Rotator Cuff Tear Arthropathy, Rheumatoid Arthritis Shoulder
- Trial name
- NCT05926622
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Medacta International SA
Burn Wound, 2nd Degree Burn of the Skin
Ultrasound Treatment on Wound Healing Time
This is a randomized, sham-controlled pilot study that will assess the safety and feasibility of splenic focused pulsed ultrasound treatment on burn wound healing time in 24 subjects (12 active ultrasound and 12 sham controls).
- Trial name
- GE-MTEC (NCT05796492)
- Testing
- Pulsed splenic ultrasound, Ultrasound probe (no energy applied)
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- General Electric Research
Metastatic Solid Tumors, Stage 4 Cancer
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
This is a sequential, dose-escalation, non-randomized, prospective, early feasibility trial. The goal of this clinical trial is to gather information on the safety and the recommended dose of the Sarah Nanotechnology System.
- Trial name
- NCT07224464
- Testing
- The Sarah Nanotechnology System - intended to deliver thermal energy to malignant cells for the purpose of thermal destruction of these cells in patients with advanced metastatic solid tumors.
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- New Phase Ltd.
Burns, Wound Healing
A Clinical Investigation to Evaluate Efficacy of Mepitel Ag in Partial Thickness Second Degree Burns
Approximately 55-65 subjects from 3-6 sites suffering from a burn injury covering 1-25% Total Body Surface Area (TBSA) will be evaluated providing they fulfill all inclusion and none of the exclusion criteria and have given a…
- Trial name
- NCT01636362
- Testing
- Mepitel Ag
- Where
- 6 sites in United States
- Volunteers
- 45 people
- Sponsor
- Molnlycke Health Care AB
Solid Tumor, Adult
A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)
This is an open-label, dose escalation and dose expansion, multi-center phase I study evaluating the safety and tolerability of CF33-CD19 administered intravenously (IV) or intratumorally (IT) in combination with blinatumomab and…
- Trial name
- OASIS (NCT06063317)
- Testing
- CF33-CD19 IT Monotherapy, CF33-CD19 IV Monotherapy, CF33-CD19 IT Combination
- Where
- 8 sites in United States
- Volunteers
- 25 people
- Sponsor
- Imugene Limited
Solid Tumors
Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer
This phase I dose escalation study is intended to define the safety, tolerability and maximal tolerable dose (MTD) of MT110 in patients with advanced solid tumors.
- Trial name
- MT110-101 (NCT00635596)
- Testing
- MT110
- Where
- 4 sites in Germany
- Volunteers
- 65 people
- Sponsor
- Amgen Research (Munich) GmbH